Breast Cancer
Conditions
Brief summary
Insomnia affects about 60% of the patients treated with radio-chemotherapy, a percentage twice higher compared to that observed in the general population. This sleep disorder increases cancer-related fatigue (CRF), the side effect most often reported by patients. Conversely, it is well accepted that adapted physical activity (APA) improves tolerance to treatment, decreases the risk of recurrence, increases survival, and reduces CRF. The present study aims to evaluate, in non-metastatic breast cancer patients, the composition and architecture of sleep by ambulatory polysomnography and to verify the effects of an APA rehabilitation program (3 times a week during 12 weeks), on the quality and quantity of sleep, daytime sleepiness. The biological markers: melatonin and body temperature will be studied to better understand the chronobiological mechanisms of the sleep-wake rhythm. Finally, the physiological responses to exercise, pain, CRF and finally quality of life will be studied at the beginning, at the end of the program and at a distance from it. Improved sleep-wake rhythm by a physical activity may reduce CRF, prevent recurrence and comorbidities.
Interventions
OTHERPhysical activity
Patients in arm A (interventional) will carry out a physical activity intervention during 3 months. Patients should perform an interval training program on cycle-ergometer during 3 sessions per week.
Sponsors
Centre Hospitalier Universitaire de Besancon
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Patients aged 18 to 65 * Patients with non-metastatic breast cancer undergoing chemotherapy * Patients with insomnia * Certificate of non-contraindication to the practice of physical activity * Women who have been postmenopausal for at least 24 months, surgically sterilized, or, for women of childbearing potential, use an effective method of contraception (oral contraceptives, contraceptive injections, intrauterine devices, double-barrier method, contraceptive patches) * Signature of informed consent to participate indicating that the subject has understood the purpose and procedures required by the study and that he agrees to participate in the study and to comply with the requirements and restrictions inherent in this study * Affiliation to a French social security scheme or beneficiary of such a scheme.
Exclusion criteria
* Patients treated with melatonin or taking hypnotics * Patients with metastases * Oxygen saturation at rest (SaO2) ≤ 92% * Patients without insomnia and / or sleep disorders * Autoimmune disease (systemic lupus erythematosus, rheumatoid arthritis) * Symptomatic osteoarthritis, cardiovascular disease (angina pectoris or uncontrolled hypertension) or lung disease (chronic obstructive pulmonary disease) * Patients suffering from malnutrition (BMI \<18 kg.m-2) or weight loss\> 10% during the previous 3 months * Patients with psychiatric or cognitive disorders deemed unsuitable for physical activity * Pregnant or breastfeeding women * Legal incapacity or limited legal capacity * Subject unlikely to cooperate with the study and / or weak cooperation anticipated by the investigator * Subject without health insurance * Subject being in the period of exclusion from another study or provided for by the national file of volunteers.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change from baseline Total sleep time at 6 months | 6 months | Evaluated with polysomnography |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change from baseline Score of fatigue at 6 months | 6 months | Evaluated with questionnaire Multidimensional Fatigue Inventory (score between 20 to 100) |
| Change from baseline body composition at 3 months | 3 months. | Evaluated bioimpedance BMI in Kg/m2 |
| Score of pain | Baseline (T0) , 3 months (T3). | Evaluated by questionnaire Brief Pain Inventory-Short Form (score between 15 to 150) |
| Inflammatory responses | Baseline (T0), 3 months (T3). | Evaluated with enzyme-linked immunosorbent assay (ELISA) |
| Change from baseline quality of sleep at 6 months | 6 months | Evaluated with actimetry |
| Basic respiratory functional exploration | Baseline (T0), 3 months (T3). | Evaluated by pneumotachography (Sensors Medics MSE, USA) for the evaluation of bronchial volumes and flows. |
| Level of anxiety | Baseline (T0), 3 months (T3), 6 months (T6). | Evaluated by questionnaire Hospital Anxiety and Depression scale (under 7 to more than 11) |
| Concentration of Melatonin | Baseline (T0), 3 months (T3), 6 months (T6). | Evaluated by saliva samples |
| Body temperature | Baseline (T0), 3 months (T3), 6 months (T6). | Evaluated by thermobuttons |
| Level of physical activity | Baseline (T0), 3 months (T3), 6 months (T6). | Evaluated with smartwatch withings with number of step |
Countries
France
Contacts
Primary ContactMOUGIN-GUILLAUME Fabienne
Outcome results
None listed